Market closed
uniQure/$QURE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About uniQure
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Ticker
$QURE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
209
Website
uniQure Metrics
BasicAdvanced
$799M
-
-$4.92
0.36
-
Price and volume
Market cap
$799M
Beta
0.36
52-week high
$19.18
52-week low
$3.73
Average daily volume
1.9M
Financial strength
Current ratio
9.744
Quick ratio
9.323
Long term debt to equity
-7,366.558
Total debt to equity
-7,419.89
Interest coverage (TTM)
-2.86%
Management effectiveness
Return on assets (TTM)
-16.39%
Return on equity (TTM)
-238.46%
Valuation
Price to revenue (TTM)
26.496
Price to book
-107.16
Price to tangible book (TTM)
-7.22
Price to free cash flow (TTM)
-3.861
Growth
Revenue change (TTM)
71.17%
Earnings per share change (TTM)
-23.90%
3-year revenue growth (CAGR)
-62.73%
3-year earnings per share growth (CAGR)
-11.23%
What the Analysts think about uniQure
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for uniQure stock.
uniQure Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
uniQure Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
uniQure News
AllArticlesVideos
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
Seeking Alpha·2 weeks ago
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting
Seeking Alpha·2 weeks ago
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for uniQure stock?
uniQure (QURE) has a market cap of $799M as of May 04, 2025.
What is the P/E ratio for uniQure stock?
The price to earnings (P/E) ratio for uniQure (QURE) stock is 0 as of May 04, 2025.
Does uniQure stock pay dividends?
No, uniQure (QURE) stock does not pay dividends to its shareholders as of May 04, 2025.
When is the next uniQure dividend payment date?
uniQure (QURE) stock does not pay dividends to its shareholders.
What is the beta indicator for uniQure?
uniQure (QURE) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.